StemCell Therapy

We are comparing Unity Biotechnology Inc. (NASDAQ:UBX) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Table 1 demonstrates Unity Biotechnology Inc. and Aeglea BioTherapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Liquidity

Unity Biotechnology Inc.s Current Ratio is 13.7 while its Quick Ratio is 13.7. On the competitive side is, Aeglea BioTherapeutics Inc. which has a 10.7 Current Ratio and a 10.7 Quick Ratio. Unity Biotechnology Inc. is better positioned to pay off short and long-term obligations compared to Aeglea BioTherapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 72.8% of Unity Biotechnology Inc. shares and 78.8% of Aeglea BioTherapeutics Inc. shares. 8.3% are Unity Biotechnology Inc.s share owned by insiders. Comparatively, 1.2% are Aeglea BioTherapeutics Inc.s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Unity Biotechnology Inc. had bearish trend while Aeglea BioTherapeutics Inc. had bullish trend.

Summary

On 7 of the 9 factors Unity Biotechnology Inc. beats Aeglea BioTherapeutics Inc.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companys lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Unity Biotechnology Inc. (UBX) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) Contrasting side by side - MS Wkly

This entry was posted on October 16, 2019 at 4:45 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |